Ro becomes care orchestration layer
Ro
The strategic issue is that once drug makers and retail health channels own supply and checkout, basic telehealth stops being the product and becomes a low value step in someone else’s funnel. Ro first won by making stigmatized prescriptions feel as easy as buying any subscription online. In GLP-1s, that edge weakened as LillyDirect, NovoCare Pharmacy, and other direct access paths turned prescription access into table stakes, pushing Ro to compete on care management, routing, and continuity instead of simple convenience.
-
Ro’s original model was highly repeatable. The same async intake, clinician review, and mail order workflow worked for ED, hair loss, and other categories, which made telehealth scalable but also easy for copycats to reproduce. That drove churn higher and made distribution and marketing costs more important than the visit itself.
-
GLP-1s briefly gave telehealth more substance because obesity treatment needs labs, dose changes, side effect monitoring, and coaching. Ro built that layer with home testing, phlebotomy, its own lab, and owned pharmacies. But after FDA declared the semaglutide shortage resolved in February 2025, manufacturer direct channels became the cleanest legal supply path.
-
Ro’s response was to plug into manufacturer distribution instead of fighting it. By mid 2025, more than half of its GLP-1 business was flowing through LillyDirect and NovoCare style channels behind a Ro front end. That keeps Ro in the patient journey, but it also means the durable value has to come from managing treatment, not controlling the drug margin.
The market is heading toward a split where commodity telehealth handles intake, while the winners own either drug supply or long term outcomes. For Ro, that points toward becoming the care orchestration layer that manufacturers, employers, and patients all rely on, with obesity management and adherence replacing one click access as the main reason to pay.